Most Read Articles
5 days ago
Among postmenopausal women, short sleep duration and depression contribute to increased fall accidents, as reported in a study.
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.

Fremanezumab reduces migraine days

Elaine Soliven
16 Aug 2019

Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, significantly reduces the number of migraine days in patients with chronic migraine (CM) or episodic migraine (EM), according to the FOCUS* study presented at AHS 2019.

This phase III, international, double-blind, parallel-group trial evaluated 838 adults diagnosed with CM or EM (aged ≤50 years) with previous inadequate responses to 2–4 classes of preventive treatments. Participants were randomized in a 1:1:1 ratio to receive subcutaneous injections of fremanezumab, either monthly** (n=283) or quarterly*** (n=276), or monthly placebo (n=278) for 12 weeks. [AHS 2019, abstract IOR08]

At baseline, the mean number of migraine days was 14.1 days for those assigned to monthly or quarterly fremanezumab and 14.3 days for those in the placebo group.

Significantly more patients treated with monthly or quarterly fremanezumab achieved a ≥50 percent reduction in monthly average number of migraine days compared with placebo at 4 weeks (36 and 38 percent, respectively, vs 10 percent; p<0.0001) and within 12 weeks after the first dose (34 percent in each group vs 9 percent; p<0.0001).

More fremanezumab recipients also experienced a reduction of ≥75 percent in monthly average number of migraine days than the placebo recipients at 4 weeks (14 percent for both the monthly and quarterly dose vs 2 percent; p<0.0001) and within 12 weeks after the first dose (12 percent vs 2 percent; p<0.0001 for the monthly dose and 8 percent vs 2 percent; p<0.005 for the quarterly dose).

A greater proportion of patients on monthly and quarterly fremanezumab sustained ≥50 percent reduction in the monthly average number of migraine days between the first 4 and 12 weeks of treatment (19 percent for monthly and 20 percent for quarterly vs 3 percent; p<0.0001) compared with placebo.

“[This] … study of fremanezumab was the first and largest study of a migraine preventive treatment in adults with both CM and EM,” said investigator Dr Egilius Spierings from MedVadis Research in Boston, Massachusetts, US, who presented the study.

“Monthly or quarterly fremanezumab treatment resulted in clinically meaningful and statistically significant reductions in migraine days … [among] patients with EM or CM ... Given the multiple previous preventive treatment failures in these patients, response rates reported here suggest [that] fremanezumab offers an effective treatment opportunity in this potentially more difficult-to-treat migraine population,” Spierings noted.

 

*FOCUS: An efficacy and safety study of fremanezumab in adults with migraine

**Monthly dosage: CM (month 1: 675 mg, months 2–3: 225 mg); EM (months 1–3: 225 mg)

***Quarterly dosage: CM or EM (month 1: 675 mg, months 2–3: placebo)

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Among postmenopausal women, short sleep duration and depression contribute to increased fall accidents, as reported in a study.
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.